progressive fibrosing interstitial lung disease
Respiratory · 2021–2021
1decision
1medicine
1carried consumer input
7individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nintedanib Treatment of adult patients with progressive fibrosing interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF). | Mar 2021 | Not recommended | 7 individuals Lung Foundation Australia |
Who spoke
Lung Foundation Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.